Wendy Maury News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Wendy maury. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Wendy Maury Today - Breaking & Trending Today
Iowa researcher suggests that gamma interferon may prevent Ebola infection outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.
BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021) BERGEN, Norway, March 6, 2021 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021. The presentation was led by BerGenBio s collaborator, Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa (Iowa City, USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to infect cell lines from the human airway, increasing the amount of virus measured in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib r ....
About AXL AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases. About Bemcentinib Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as ....
BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.